Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.
In 2011-2012, a survey was performed in three regional hospitals in the Czech Republic to determine the incidence of Clostridium difficile infections (CDIs) and to characterize bacterial isolates. C. difficile isolates were characterized by PCR ribotyping, toxin genes detection, multiple-locus variable-number tandem-repeat analysis (MLVA), and antimicrobial susceptibility testing to fidaxomicin, vancomycin, metronidazole, clindamycin, LFF571, and moxifloxacin using agar dilution method. The incidence of CDI in three studied hospitals was 145, 146, and 24 cases per 100,000 inhabitants in 2011 and 177, 258, and 67 cases per 100,000 inhabitants in 2012. A total of 64 isolates of C. difficile was available for molecular typing and antimicrobial susceptibility testing. 60.9% of the isolates were classified as ribotype 176. All 41 isolates of ribotypes 176 and 078 were positive for the presence of binary toxin genes. Ribotype 176 also carried 18-bp deletion in the regulatory gene tcdC. Tested isolates of C. difficile were fully susceptible to vancomycin and metronidazole, whereas 65.1% of the isolates were resistant to moxifloxacin. MLVA results indicated that isolates from three different hospitals were genetically related, suggesting transmission between healthcare facilities.
Czech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. vladimir.beran@osu.cz.
V
http://orcid.org/0000-0001-8702-6606
V
Beran
Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
E J
EJ
Kuijper
Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
C
C
Harmanus
Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
I M
IM
Sanders
Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
S M
SM
van Dorp
Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands.
C W
CW
Knetsch
Department of Infection Diagnosis, Litomysl Hospital, The Hospital of Pardubice Region, Pardubice, Czech Republic.
J
J
Janeckova
Department of Clinical Immunology and Microbiology, Regional Hospital of Nachod, Nachod, Czech Republic.
A
A
Seidelova
Department of Clinical Microbiology, Pardubice Hospital, The Hospital of Pardubice Region, Pardubice, Czech Republic.|Department of Epidemiology, Faculty of Military Health Sciences, Hradec Kralove, University of Defense, Brno, Czech Republic.
L
L
Barekova
Department of Computer Science, Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
J
J
Tvrdik
Czech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
D
D
Chmelar
Czech Anaerobic Bacteria Reference Laboratory, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
I
I
Ciznar
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001427:Bacterial Toxins / Q000032:analysis* / Q000235:genetics; D016360:Clostridioides difficile / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D003015:Clostridium Infections / Q000453:epidemiology* / Q000382:microbiology*; D018153:Czech Republic / Q000453:epidemiology; D052978:Disk Diffusion Antimicrobial Tests; D006761:Hospitals; D006801:Humans; D015994:Incidence; D018598:Minisatellite Repeats; D058889:Molecular Typing; D021521:Ribotyping
D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins